We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+1.74%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.1B
AUM Growth
+$59.7M
(+0.85%)
Cap. Flow
-$1.53B
Cap. Flow
% of AUM
-21.52%
Top 10 Holdings %
Top 10 Hldgs %
75.68%
Holding
101
New
15
Increased
16
Reduced
17
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$78.6M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$57.7M |
| 3 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$22.5M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
+$15.4M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPHM
VIROPHARMA INC
VPHM
|
+$220M |
| 2 |
Gilead Sciences
GILD
|
+$48M |
| 3 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$35.3M |
| 4 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$24.5M |
| 5 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$24.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.41% |
| 2 | Miscellaneous | 49.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSRO
76
DELISTED
TESARO, Inc.
TSRO
| $882K | 0.01% |
31,218
| – | – |
|
77
Galectin Therapeutics
GALT
$387M
| $813K | 0.01% |
+100,600
| New | +$929K |
|
|
FMI
78
DELISTED
Foundation Medicine, Inc.
FMI
| $476K | 0.01% |
+20,000
| New | +$559K |
|
|
FPRX
79
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $333K | ﹤0.01% |
+19,823
| New | +$246K |
|
|
SLXP
80
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $326K | ﹤0.01% |
3,621
| – | – |
|
|
CCXI
81
DELISTED
ChemoCentryx, Inc.
CCXI
| $290K | ﹤0.01% |
50,000
-150,000
| -75% | -$773K |
|
82
Gyre Therapeutics
GYRE
$709M
| – | – |
-2,626
| Closed | -$11M |
|
|
LITS
83
Lite Strategy Inc
LITS
$39.1M
| – | – |
-17,266
| Closed | -$3.88M |
|
|
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| – | – |
-586,936
| Closed | -$10.2M |
|
|
ARIA
85
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| – | – |
-1,333,703
| Closed | -$24.5M |
|
|
CBST
86
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| – | – |
-5,000
| Closed | -$318K |
|
|
VPHM
87
DELISTED
VIROPHARMA INC
VPHM
| – | – |
-5,592,239
| Closed | -$220M |
|
Similar funds
ASRS
FWIA
CWP
SFA
MGP
JAM
Baker Bros. Advisors's Q4 2013 Portfolio in Review
As of Q4 2013, Baker Bros. Advisors held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Baker Bros. Advisors withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier, followed by Miscellaneous.
Against the trend, Baker Bros. Advisors opened a new position in DYAX CORPORATION worth $15.3M.
- Baker Bros. Advisors's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
- Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
- Baker Bros. Advisors's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
- Baker Bros. Advisors fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
- Baker Bros. Advisors's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
- Baker Bros. Advisors opened 15 new positions and closed 6 in Q4 2013.
- Baker Bros. Advisors's portfolio value rose 0.85% quarter-over-quarter to $7.1B.
Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.